Prelude Therapeutics Incorporated

PRLDNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
4.54 USD
↗ 0.02 (0.33%)🟢PRE MARKET (AS OF 07:31 PM EDT)
🟢Market: OPEN

Prelude Therapeutics Incorporated (PRLD) trades at $4.54 per share. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. PRLD is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Sep 15, 2026.

Open?$4.56
High?$4.63
Low?$4.40
Prev. Close?$4.52
Volume?232.4K
Avg. Volume?495.5K
VWAP?$4.46
Rel. Volume?0.47x
Bid / Ask
Bid?$3.75 × 100
Ask?$5.17 × 100
Spread?$1.42
Midpoint?$4.46
Valuation & Ratios
Market Cap?360.7M
Shares Out?79.8M
Float?17.1M
Float %?39.0%
P/E Ratio?N/A
P/B Ratio?2.70
EPS?-$0.76
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyHealthcare - Genomics & Precision Medicine›Precision Medicine Platforms
Employees
79
Market Cap
366.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.preludetx.com
Listed
2020-09-25
Address
175 INNOVATION BOULEVARD
WILMINGTON, DE 19805
Phone: (302) 467-1280
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
56
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.65Distress
Confidence?49%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?21.08%Squeeze Risk
Short Interest?3.6M
Days to Cover?5.6
Free Float17.1M
Avg Daily Volume643.3K
Settlement Date2026-08-31
Financial Health
Current Ratio?4.07Strong
Quick Ratio?4.07Strong
Cash Ratio?0.69Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
61
2.70CHEAP▾
P/S?
Peers
100
S&P
3
16.09HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.1CHEAP▾
EV/Sales?
Peers
100
S&P
3
14.91HIGH▾
Returns & Efficiency
ROE?
S&P
3
-45.2%WEAK▾
ROA?
S&P
3
-31.9%WEAK▾
Cash Flow & Enterprise
FCF?$-33255000
Enterprise Value?$334.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist